SAVA Q3 2022 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena

SAVACassava Sciences, Inc.

$115M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$19M

Operating Income

-$21M

Net Income

-$20M

EPS (Diluted)

$-0.48

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$470,000

Balance Sheet

Total Assets

$207M

Total Liabilities

$9M

Stockholders' Equity

$199M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$19M	-$8M	-130.4%
Operating Income	-$21M	-$10M	-118.9%
Net Income	-$20M	-$10M	-111.8%